- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KARDIGAN Aktie jetzt für 0€ handeln | |||||
| Mo | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | 2 | Investing.com | ||
| Mo | Kardigan: TD Cowen startet Coverage mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| Mo | JPMorgan initiates Kardigan stock with overweight on pipeline | 2 | Investing.com | ||
| Mo | Jefferies initiates Kardigan stock with buy rating on cardiology pipeline | 1 | Investing.com | ||
| Mo | JPMorgan startet Kardigan-Aktie mit "Overweight" - Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| Mo | Jefferies startet Kardigan mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 23.06. | How Kardigan spun deal leftovers into a $400M IPO | 1 | BioPharma Dive | ||
| 23.06. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.06. | Kardigan erzielt 460 Millionen US-Dollar bei Börsengang an der NASDAQ | 2 | Investing.com Deutsch | ||
| 22.06. | Kardigan closes $460 million IPO on Nasdaq | 1 | Investing.com | ||
| 22.06. | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 249 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| 18.06. | Kardigan's IPO Lands $400M for Drugs That Get to Root Causes of Heart Diseases | 1 | MedCity News | ||
| 18.06. | Kardigan rises in Nasdaq debut after upsized $400 million IPO | 2 | Reuters | ||
| 18.06. | Kardigan rises on market debut after upsized IPO | 3 | Seeking Alpha | ||
| 18.06. | Heart drug biotech Kardigan raises $400m in upscaled IPO | 1 | pharmaphorum | ||
| 18.06. | Cardiovascular diseases biotech Kardigan prices upsized IPO at $16, the high end of the range | 2 | Renaissance Capital | ||
| 18.06. | Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3 | 3 | FierceBiotech | ||
| 18.06. | Cardiovascular biotech Kardigan prices upsized $400M IPO at $16/share | 1 | Seeking Alpha | ||
| 18.06. | Kardigan prices IPO at $16 per share, raising $400 million | 2 | Investing.com | ||
| 18.06. | Kardigan, Inc. Announces Pricing of Upsized Initial Public Offering | 293 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,935 | -1,53 % | Was Insider bei InnoCan Pharma noch vor Börsenschluss bereits wissen: Das Signal das die meisten Anleger noch nicht kennen - Was erfahrene Trader jetzt tun | ||
| JAGUAR HEALTH | 2,170 | 0,00 % | Jaguar Health, Inc. - 8-K, Current Report | ||
| KALA BIO | 0,962 | -0,14 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,500 | +0,57 % | Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer | ||
| GALECTIN THERAPEUTICS | 4,420 | -5,56 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,460 | 0,00 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,590 | +0,89 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,320 | +1,54 % | InMed Pharmaceuticals Inc. - 8-K, Current Report | ||
| KIORA PHARMACEUTICALS | 2,500 | +0,81 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual... ► Artikel lesen | |
| MINDWALK | 1,270 | -0,78 % | MindWalk Holdings Corp. - 6-K, Report of foreign issuer | ||
| LIPOCINE | 2,310 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,372 | +2,71 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| HARROW | 35,000 | -1,13 % | Harrow, Inc.: Harrow Health, Inc. Announces Commercial Launch of BYOOVIZ in the United States | NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of... ► Artikel lesen | |
| INVENTIVA | 3,770 | -0,40 % | INVENTIVA: Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants | Daix (France), New York City (New York, United States), July 9, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| MEDICINOVA | 1,380 | +0,73 % | MediciNova, Inc.: MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment | LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen |
Das Unternehmen KARDIGAN INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,67 % bei einem Aktienkurs von 22,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KARDIGAN INC finden Sie auf Wallstreet Online.